Human Anti-MS4A1 Recombinant Antibody (clone B9E9) (CAT#: FAMAB-1218CQ)

Figure 1 Raji cells were incubated with either diluent (line indicating 0 μM) or lovastatin (1-20 μM) for 48 h.

Then, 1×10^6/ml of cells were incubated with saturating amounts of FITC-conjugated anti-CD20 mAb (B9E9) or IgG1 (isotype control) for 30 min at room temperature in the dark. Binding of mAb to Raji cells was measured with flow cytometry.

Winiarska, M., Bil, J., Wilczek, E., Wilczynski, G. M., Lekka, M., Engelberts, P. J., ... & Nowis, D. (2008). Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med, 5(3), e64.

Figure 2 Immunofluorescence studies of Raji cells incubated for 48 h with either diluent or 10 μM lovastatin.

Raji cells were incubated with FITC-conjugated (green) mAb (B9E9) to detect the extracellular (conformational) epitope located in the larger CD20 loop. Upon washing with PBS, the cells were permeablized with acetone and incubated with IgG1 mAb (NCL-CD20-L26) directed against a cytoplasmic (linear) epitope within CD20 molecule. After washing, a secondary Alexa555-labeled (red) anti-IgG1 (anti-NCL-CD20-L26) mAb was used. Bar = 50 μm.

Winiarska, M., Bil, J., Wilczek, E., Wilczynski, G. M., Lekka, M., Engelberts, P. J., ... & Nowis, D. (2008). Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med, 5(3), e64.